Company logo Company name logo
Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.     |     Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors.     |     KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |     ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
tiker sep
plus stop minus
 
 
Natco Pharma LtdIndustry : Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code:524816NSE Symbol: NATCOPHARMP/E(TTM):17.28
ISIN Demat:INE987B01026Div & Yield %:0.58EPS(TTM):45.47
Book Value(Rs):501.202063Market Cap (rupee Cr.):15408.99Face Value(Rs):2
    
Date Headline
19-Oct-26 Natco Pharma launches Carboplatin Injection in U.S. market
23-Sep-26 Natco Pharma to consider Fund Raising
09-Sep-26 Natco Pharma board approves rights issue of Rs1,300 cr
05-Sep-26 Natco Pharma to conduct board meeting
05-Sep-26 Natco Pharma to conduct AGM
25-Aug-26 Natco Pharma to further invest USD 14M in eGenesis Inc.
24-Aug-26 Stock Alert: Caplin Point Lab, Natco pharma, Federal Bank, B. R. Goyal Infra
22-Aug-26 Natco Pharma announces conclusion of USFDA inspection of its Visakhapatnam unit
22-Aug-26 NATCO Pharma's Visakhapatnam unit gets Form 483 with 4 observations from US FDA
14-Aug-26 Board of Natco Pharma recommends interim dividend
<< < 1 2 3 4   > >>